Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
Apellis Pharmaceuticals, a leader in complement medicine, announced its participation in two upcoming March investor conferences: Cowen 43rd Annual Healthcare Conference: Fireside chat on March 8, 2023, at 9:10 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Apellis Pharmaceuticals, a leader in complement medicine, announced its participation in two upcoming March investor conferences:
- Cowen 43rd Annual Healthcare Conference: Fireside chat on March 8, 2023, at 9:10 a.m. ET.
- Oppenheimer’s 33rd Annual Healthcare Conference: Virtual fireside chat on March 13, 2023, at 3:20 p.m. ET.
Both events will have live webcasts available on the company’s website, with replays accessible for 90 days. Apellis focuses on innovative therapies aimed at complex diseases, boasting two approved medications for targeting complement C3. For more details, visit apellis.com.
Details
News Market Reaction – APLS
The recorded move for APLS in the trading session of this news was -2.26%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will participate in the following March investor conferences:
- Cowen 43rd Annual Healthcare Conference: Fireside chat on Wednesday, March 8, 2023, at 9:10 a.m. ET.
- Oppenheimer’s 33rd Annual Healthcare Conference: Virtual fireside chat on Monday, March 13, 2023, at 3:20 p.m. ET.
Each conference event will be available via a live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcasts will be available for 90 days following the event.
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first and only therapy for geographic atrophy, a leading cause of blindness around the world. With nearly a dozen clinical and pre-clinical programs underway, we believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn.
Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.